Mycobacterium Tuberculosis Infection Prevention
Monday, 24 March 2014 09:00 - 17:00
Cineworld: The O2, London, SE10 0DX, UK
This event will discuss new ways being developed to control and prevent TB Infection. Including discussion about cost effectiveness of current treatments, developing vaccines and transmission prevention, this event will be an ideal setting for discussion , debate and discovering current thinking and what is new in the field.
This event is part of the 2014 TB Summit - www.TBSummit2014.com. This event has CPD accreditation.
The deadline for abstract submissions for oral presentation is January 10th 2014.
Abstracts for poster presentation only can be submitted up to two weeks before the event
You can download the instructions for authors at
www.euroscicon.com/AbstractsForOralAndPosterPresentation.pdf
Talk times include 5 – 10 minutes for questions
9:00 – 9:45 Registration
9:45 – 10:00 Introduction by the Chair
10:00 – 10:30 Tackling TB in the Age of Austerity: ensuring we use novel tools and approaches cost-effectively
Dr Peter J White, (1) Head, Modelling and Economics Unit, Public Health England and (2) School of Public Health, Imperial College London
TB diagnoses in the UK remain high, having risen for two decades, and novel approaches to control are urgently needed. Limited resources mean interventions must be cost-effective, which requires effective targeting of both case-finding and support for treatment adherence. Assessing cost-effectiveness involves considering not just the benefits to individuals who are diagnosed and treated, but also calculation of how much transmission is averted by earlier treatment of active disease, or treatment of latent infection, which prevents active disease from occurring at all. We use mathematical modelling to evaluate novel approaches to finding patients, new diagnostics, and treatment approaches.
10:30 – 11:00 To be confirmed
11:00 – 11:30 Speakers’ photo then mid-morning break and poster exhibition and trade show
11:30 – 12:00 An unbiased genome-wide Mycobacterium tuberculosis gene-expression approach to discover new antigens for human T cells that are expressed during pulmonary infection
Professor Tom HM Ottenhoff, Professor in Immunology, Leiden University Medical Center, The Netherlands
A prerequisite for candidate vaccine antigens is that they are immunogenic and expressed by Mtb during infection of the primary target organ: the lungs of susceptible individuals. We have used a genome-wide, unbiased antigen discovery approach to investigate the in vivo expression of 2170 Mtb genes during Mtb infection in the lungs of mice. To study the vaccine potential of these proteins, we analyzed their immunogenicity. These in vivo expressed TB antigens (IVE-TB) antigens, expressed during pulmonary infection in vivo, were immunogenic, induced strong (memory) T cell responses in long-term latently Mtb infected individuals and thus may represent attractive antigens for new TB vaccines. IVE antigen discovery approaches can be applied to other infectious diseases.
12:00 – 12:30 Oral Presentations
12:30 – 13:30 Lunch, poster exhibition and trade show
13:30 – 15:00 Question and Answer Session
15:00 – 15:30 Afternoon Tea, last poster session and trade show
15:30 – 16:00 Whole genome sequencing to target public health control measures for tuberculosis
Dr Timothy Walker, MRC Research Training Fellow and Infectious Diseases and Microbiology Registrar, University of Oxford, UK
As a typing method, whole genome sequencing of M. tuberculosis offers unprecedented resolution and offers the prospect of delineating outbreaks of disease even in the absence of epidemiological data. I will present some of the ground work that has been done in this relatively new field and will also discuss the resutls of population based studies in Oxfordshire and Birmingham.
16:00 – 16:30 Neutrophils and B-lymphocytes in experimental TB: from the outcast to competent players
Professor Alexander Apt, Professor and Head, Laboratory for Immunogenetics, Central Institute for Tuberculosis, Moscow, Russia
Extremely short life span of neutrophils, rapid replacement of their pool, capacity to engulf and kill different bacteria without obvious cooperation with other cells of the immune system implied the conclusion that these cells have little to do with sophisticated immune responses during chronic TB. Similarly, classical animal studies based upon adoptive transfer of immune lymphocytes and sera tightly linked anti-TB immunity with macrophages activated by T-cells, leaving a very limited role for B-cells. Recent findings dramatically changed these views. A deeper insight in the involvement of neutrophils and B-cells in complex networks of granulomatous inflammation and immune response regulation is displayed in this talk.
16:30 - 17:00 Chairman’s summing up
Registration Website: http://www.regonline.co.uk/TBPrevention2014
About the Speakers
Peter White is a member of the UK government’s Scientific Pandemic Influenza advisory committee modelling sub-group (SPI-M), and during the 2009 pandemic he led real-time modelling to advise government, and contributed to ECDC and WHO modelling working groups. He led health economic modelling work contributing to recent NICE guidance on TB in hard-to-reach groups, performed an evaluation of the London TB Find and Treat Service for the Department of Health, and has ongoing work in TB funded by NIHR. He is leading modelling work funded by the Technology Strategy Board developing a user-friendly tool for planning chlamydia testing services.
Tom HM Ottenhoff is a Professor in Immunology 2001-present at LUMC/Univ Leiden. He has been a visiting Professor at Stanford Univ. April-August 2008, Associate professor at LUMC 1993-2001 (LUMC), Visiting Professor at NIH. 1991-1993, Huygens Fellow 1989-1993 (LUMC), Senior Scientist at Armauer Hansen Research Inst 1986-1988 and carried out his PhD research training at LUMC 1982-1986.
Tim Walker is an Infectious Disease and Microbiology registrar in Oxford and is currently working as an MRC Research Training Fellow with the UK-CRC Modernising Medical Microbiology consortium.
Alex Apt graduated from Lomonosov Moscow State University in 1973 and joint TB community about 35 years ago after initial training in the MHC immunogenetics. He heads the Laboratory for Immunogenetics at the Central Institute for Tuberculosis, Moscow, since 1998. The main activity of his lab includes application of mouse TB models to identification of genes involved in TB control, gene expression analyses, lung tissue pathology and immune cell interactions. The models developed in the lab are also used for vaccine and drug testing.
Post expires at 2:01pm on Monday March 24th, 2014
Tags: air filter, antigen discovery, Antimycobacterial activity, arabinogalactan, B cells, benzothiazinone, cell wall, cost-effectiveness, diagnosis, drug discovery, epidemiology, evaluation, Fluoroquinolone resistance, granuloma, gyrA, gyrB, health economics, IGRA, infection, inhA, Isoniazid resistance, katG, latent, Latent TB; M/XDRTB; genome; proteome; immunome, Mangosteen extract, mice, mutation, Mycobacterium tuberculosis, Neutrophils, outbreaks, pre-filter, protective immunity, Rifampicin resistance, rpoB, T cells, TB, Thailand, transmission-dynamic modelling, tuberculosis, tuberculosis vaccines, tuberculosis; treatment; biomarkers; antibiotics, Whole genome sequencing
Follow Us!